Business Description
Molecular Partners AG
ISIN : CH0256379097
Compare
Compare
Traded in other countries / regions
MOLN.SwitzerlandMOLN.USA0QXX.UK6ML.Germany IPO Date
2018-06-14Description
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 52.28 | |||||
| Equity-to-Asset | 0.9 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.05 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 5.41 | |||||
| Beneish M-Score | -1.41 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -16.9 | |||||
| 3-Year EBITDA Growth Rate | 8.7 | |||||
| 3-Year EPS without NRI Growth Rate | 9.4 | |||||
| 3-Year FCF Growth Rate | -14.1 | |||||
| 3-Year Book Growth Rate | 13.4 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | -4.75 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 39.66 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 72.41 | |||||
| 9-Day RSI | 67.65 | |||||
| 14-Day RSI | 64.18 | |||||
| 6-1 Month Momentum % | 18.42 | |||||
| 12-1 Month Momentum % | 13.92 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 14.33 | |||||
| Quick Ratio | 14.33 | |||||
| Cash Ratio | 13.76 | |||||
| Days Sales Outstanding | 145.32 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -4.1 | |||||
| Shareholder Yield % | 0.6 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -1050.83 | |||||
| Net Margin % | -1042.84 | |||||
| FCF Margin % | -1056.39 | |||||
| ROE % | -37.46 | |||||
| ROA % | -33.76 | |||||
| ROIC % | -711.94 | |||||
| 3-Year ROIIC % | 6.58 | |||||
| ROC (Joel Greenblatt) % | -1187.49 | |||||
| ROCE % | -36.21 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 29.67 | |||||
| PB Ratio | 1.29 | |||||
| Price-to-Tangible-Book | 1.29 | |||||
| EV-to-EBIT | -0.93 | |||||
| EV-to-Forward-EBIT | 0.85 | |||||
| EV-to-EBITDA | -0.96 | |||||
| EV-to-Forward-EBITDA | 0.4 | |||||
| EV-to-Revenue | 9.67 | |||||
| EV-to-Forward-Revenue | 0.31 | |||||
| EV-to-FCF | -0.92 | |||||
| Price-to-Net-Current-Asset-Value | 1.34 | |||||
| Price-to-Net-Cash | 1.4 | |||||
| Earnings Yield (Greenblatt) % | -107.53 | |||||
| FCF Yield % | -31.64 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:MLLCF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Molecular Partners AG Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 6.813 | ||
| EPS (TTM) ($) | -2.17 | ||
| Beta | 1.5 | ||
| Volatility % | 43.38 | ||
| 14-Day RSI | 64.18 | ||
| 14-Day ATR ($) | 0.080932 | ||
| 20-Day SMA ($) | 6.015 | ||
| 12-1 Month Momentum % | 13.92 | ||
| 52-Week Range ($) | 3.66 - 6.7 | ||
| Shares Outstanding (Mil) | 36.84 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Molecular Partners AG Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Molecular Partners AG Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Molecular Partners AG Frequently Asked Questions
What is Molecular Partners AG(MLLCF)'s stock price today?
The current price of MLLCF is $6.35. The 52 week high of MLLCF is $6.70 and 52 week low is $3.66.
When is next earnings date of Molecular Partners AG(MLLCF)?
The next earnings date of Molecular Partners AG(MLLCF) is 2024-11-26 Est..
Does Molecular Partners AG(MLLCF) pay dividends? If so, how much?
Molecular Partners AG(MLLCF) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers